<DOC>
	<DOCNO>NCT01515046</DOCNO>
	<brief_summary>This phase II study . It design provide information high-dose ascorbate ( vitamin C ) increase survival pancreatic cancer patient . The hypothesis vitamin C well tolerate increase cancer treatment effectiveness , lengthen survival time patient advance pancreatic cancer .</brief_summary>
	<brief_title>Clinical Trial High-dose Vitamin C Advanced Pancreatic Cancer</brief_title>
	<detailed_description>Adenocarcinoma pancreas fourth lead cause cancer death United States increase incidence ; prognosis remain dismal . We propose investigate entirely new approach , use pharmacological ascorbate , combine Gemcitabine , treat cancer . Intravenous ascorbate ( i.e. , ascorbic acid , vitamin C ) , oral ascorbate , produce high plasma concentration , range cytotoxic tumor cell . Though ascorbate utilized cancer therapy , study investigate intravenous deliver ascorbate . Preliminary study group demonstrate ascorbate induces oxidative stress cytotoxicity pancreatic cancer cell ; cytotoxicity appear great tumor vs. normal cell . We hypothesize production H2O2 mediates increase susceptibility pancreatic cancer cell ascorbate-induced metabolic oxidative stress . Gemcitabine standard chemotherapy drug use treat pancreatic cancer .</detailed_description>
	<mesh_term>Pancreatic Neoplasms</mesh_term>
	<mesh_term>Vitamins</mesh_term>
	<mesh_term>Ascorbic Acid</mesh_term>
	<mesh_term>Gemcitabine</mesh_term>
	<criteria>Patients must cytological histological diagnosis adenocarcinoma arise pancreas . Diagnosis metastatic sampling acceptable . Disease must measure radiologically . Failed initial therapy ineligible definitive curative therapy . If prior treatment include radiation therapy , recurrent disease must outside targeted volume . Age ≥ 18 year ECOG performance status 02 ( Karnofsky &gt; 50 % , see Appendix A ) . Patients must normal organ marrow function define : leukocyte ≥ 3,000/mm3 absolute neutrophil count ≥ 1,500/mm3 platelet ≥ 100,000/mm3 total bilirubin &lt; 2x institutional upper limit normal AST ( SGOT ) &lt; 3x institutional upper limit normal OR &lt; 5x institutional upper limit normal patient present liver metastasis ALT ( SGPT ) &lt; 3x institutional upper limit normal OR &lt; 5x institutional upper limit normal patient present liver metastasis PT/INR within normal institutional limit , unless patient warfarin antithrombotic agent creatinine &lt; 1.5 X institutional upper limit normal OR creatinine clearance ≥ 60 mL/min/1.73 m2 patient creatinine level institutional normal . Not pregnant . Women childbearing potential men must agree use adequate contraception ( hormonal barrier method birth control ; abstinence ) prior study entry duration study participation . Should woman become pregnant suspect pregnant participating study , inform treat physician immediately . Ability understand willingness sign write informed consent document . Prior chemotherapy treat metastatic disease . Adjuvant therapy ( include radiation therapy ) within 4 calendar week . Unresolved toxicity prior therapy malignancy . G6PD ( glucose6phosphate dehydrogenase ) deficiency . Second malignancy nonmelanoma skin cancer within past 5 year . Excess consumption alcohol excess alcohol define four one follow per day : 30 mL distil spirit , 340 mL beer , 120 mL wine . Uncontrolled intercurrent illness include , limited ongoing active infection , symptomatic congestive heart failure , unstable angina pectoris , cardiac arrhythmia , psychiatric illness/social situation , condition would limit compliance study requirement determine study team member . Pregnant lactating woman : The risk chemotherapy fetus/infant well document .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2017</verification_date>
	<keyword>Vitamins</keyword>
	<keyword>Complementary medicine</keyword>
	<keyword>Pancreatic cancer</keyword>
	<keyword>Ascorbate</keyword>
	<keyword>Ascorbic Acid</keyword>
	<keyword>Antioxidants</keyword>
	<keyword>Gemcitabine</keyword>
	<keyword>Pharmacologic action</keyword>
</DOC>